Binodenoson (MRE-0470) - The Next Generation in Cardiovascular Disease Diagnostics

Cardiac Stress Tests
Cardiac stress tests allow physicians to identify the presence of cardiovascular disease by examining the flow of blood through the heart. Patients have traditionally achieved the coronary blood vessel dilation necessary for these tests by exercising on a treadmill. However, many patients cannot complete the required treadmill exercise due to age or infirmity. For them, blood vessel dilation is achieved through the use of pharmacological stress agents. Approximately 2.6 million of these pharmacological tests are performed each year in the United States alone.

The Aderis Approach
Adenosine-based pharmacological stress agents, the existing agents of choice for cardiovascular disease diagnostics, are not able to distinguish between the four types of adenosine receptors in the heart. Rather than stimulate the single receptor necessary for increased cardiac blood flow, these agents stimulate all four receptors, causing side effects such as low blood pressure, wheezing and a dangerously slow heart rate.

Aderis' novel coronary artery disease diagnostic, Binodenoson, is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A_2A receptor. This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion.

Development & Commercialization
Aderis has partnered with King R&D, a subsidiary of King Pharmaceuticals, for development and commercialization of Binodenoson. King initiated Phase III trials of Binodenoson in December 2003.

back to top

---